PF-06882961

DB16043InvestigationalSmall molecule

PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

Mechanism: Pharmacologically active on Glucagon-like peptide 1 receptor
Curator reviewed
Formula / weight: C₃₁H₃₀FN₅O₄ · 555.61 g/mol (avg)
Also known as: danuglipron
Code names: PF-06882961

Resolves to

Compound

UNIIDN9IUI24GPCAS2230198-02-2

Structure

InChIKeyHYBAKUMPISVZQP-DEOSSOPVSA-NSMILESOC(=O)C1=CC=C2N=C(CN3CCC(CC3)C3=NC(OCC4=CC=C(C=C4F)C#N)=CC=C3)N(C[C@@H]3CCO3)C2=C1

Targets

P43220GLP1R

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-06882961, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account